SQ Ketamine in Senior Dogs: What We Actually Know

Patient selection, dosing intervals, and the limits of the evidence

Ketamine usually enters the conversation when a senior dog’s pain plan is no longer doing enough, and comorbidities, adverse effects, or an incomplete response limit the usual options.

Most veterinarians already know ketamine can provide analgesia. The harder question is how to use it in a dog with chronic osteoarthritis (OA), especially when that dog also has cardiac, renal, hepatic, or neurologic disease.

The evidence is much stronger for perioperative ketamine than for chronic pain. Low-dose ketamine constant rate infusions (CRIs) have been studied in dogs after limb amputation and mastectomy. Some clinicians are also using intermittent subcutaneous (SQ) ketamine for chronic pain, but that use is driven mainly by clinical experience. No controlled canine trial has established the best SQ dose, treatment interval, duration of benefit, or long-term safety for chronic OA.

Ketamine may still have a place in a senior pain plan. We need to be clear about which type of use we mean, what problem we are trying to solve, and how we will decide whether it helped.

Key Takeaways

• Ketamine is an NMDA receptor antagonist used as an adjunct within a multimodal pain plan, not as a stand-alone analgesic.
• The strongest canine evidence supports low-dose ketamine CRIs for acute perioperative pain. Those studies do not establish efficacy for repeated treatment of chronic OA.
• There is no standardized, evidence-based SQ ketamine protocol for chronic pain in dogs. The common 0.5 mg/kg SQ dose at intervals from weekly to every four weeks reflects anecdotal clinical use, not a validated schedule.
• A perioperative CRI, a monitored infusion for an acute pain flare, and intermittent SQ treatment are three different applications with three different levels of evidence.
• Age alone is not a contraindication. Disease status, frailty, current medications, organ function, and monitoring capacity matter more than the number on the chart.
• Before trying ketamine, decide what improvement would look like and measure the same functional tasks before and after treatment.

What Ketamine Adds to a Pain Plan

Ketamine is a noncompetitive NMDA receptor antagonist. With ongoing nociceptive input, NMDA receptor activation in the dorsal horn contributes to central sensitization and wind-up. The nervous system becomes more responsive to incoming signals, and pain can persist or amplify beyond what peripheral inflammation alone would explain.

At subanesthetic doses, ketamine is used for its antihyperalgesic and analgesic effects. It may help reduce central sensitization, but it is not expected to carry a chronic pain plan on its own. In practice, it sits alongside treatments for the dog’s other pain contributors: an NSAID where tolerated, rehabilitation, weight and muscle management, environmental changes, and other pharmacologic therapies.

That changes how we judge the response. We are not looking for a change on radiographs. We are looking for a dog who rises more easily, walks farther, rests more comfortably, or returns to an activity that pain had taken away.

Three Ways Ketamine Is Used for Pain in Dogs

When a veterinarian says “I use ketamine for pain,” that can mean three very different protocols.

1. Perioperative ketamine CRI

This is the best-studied use in dogs. Ketamine is incorporated into a balanced anesthetic and analgesic protocol as a loading dose followed by a CRI. The goals are to reduce central sensitization, improve perioperative analgesia, and reduce the requirement for other anesthetic or analgesic drugs.

Timing may matter. In one canine ovariohysterectomy study, preoperative ketamine produced lower and more consistent postoperative pain scores than postoperative administration. If ketamine is part of the plan for a senior dog undergoing a dental procedure, amputation, orthopedic surgery, or another painful intervention, it is likely most useful when it is on board before substantial nociceptive input and central sensitization occur.

The Merck Veterinary Manual lists a canine loading dose of 0.5 to 1 mg/kg IV followed by 0.12 to 0.6 mg/kg/hour IV as a CRI. These are reference ranges for acute analgesic use. They are not a chronic OA protocol, and they do not replace patient-specific anesthetic planning and titration.

2. A monitored infusion for an acute pain flare

Some clinicians use a time-limited infusion in a hospitalized patient with severe or refractory pain. Consider this when a dog has an acute flare or suspected central sensitization despite an existing multimodal plan. The dose, duration, concurrent medications, and monitoring depend on the patient and the setting.

This is a different clinical decision from giving intermittent SQ ketamine to an outpatient with chronic OA. The expected response and the evidence base are not interchangeable.

3. Intermittent SQ ketamine for chronic pain

This use generates most of the questions we hear from general practitioners and mobile veterinarians. It is appealing because it does not require a syringe pump or hours of hospitalization. It also has the least canine evidence.

Published veterinary guidance describes 0.5 mg/kg SQ weekly or less often, with the possibility of more frequent administration in severe cases, and notes that these recommendations are anecdotal and based on the author’s experience. Clinically, some veterinarians give 0.5 mg/kg SQ every 1 to 4 weeks, then adjust the interval based on the dog’s response and apparent duration of benefit.

Neither the dose nor the one-to-four-week interval has been validated in a controlled canine chronic-pain trial. That does not make the protocol unusable. It does mean we should describe it accurately to clients, document why we chose it, and reassess rather than leaving the patient on an indefinite schedule by default.

One point worth stating plainly: SQ ketamine is an adjunct. It does not replace primary analgesia, and it should not be the only thing a painful dog goes home on.

What the Canine Evidence Shows

The studies most often cited in dogs evaluated acute postoperative pain.

In a randomized study of dogs undergoing forelimb amputation, Wagner and colleagues started low-dose ketamine before surgery and continued it by CRI for 18 hours afterward. Dogs receiving ketamine had lower pain scores during the study period and greater activity for up to three days after surgery than controls.

In dogs undergoing mastectomy, Sarrau and colleagues evaluated an IV loading dose followed by a six-hour postoperative CRI. The ketamine group showed better feeding behavior for up to 20 hours after the infusion.

Both studies support ketamine as a perioperative analgesic adjunct. Neither tells us how repeated SQ ketamine performs in dogs with naturally occurring chronic OA.

A 2025 systematic review evaluated 14 studies of perioperative systemic ketamine in dogs and cats. Overall evidence quality was rated moderate, although many studies were small, underpowered, and focused on soft-tissue procedures. Ketamine may influence pain scores for more than 12 hours after surgery, but the review did not find a clear reduction in rescue-analgesia requirements. A change in pain scores does not automatically translate into consistent opioid-sparing or rescue-analgesia effects.

The review also found that plasma concentrations above 200 ng/mL correlated with changes in nociceptive thresholds, and that concentrations fell quickly once an IV bolus or infusion ended. That helps explain exposure and antinociception, but experimental thresholds don’t match meaningful improvement in a dog with chronic OA.

Which raises a fair question: if ketamine clears that quickly, why would anyone dose it weekly or monthly? The reasoning is mechanistic. NMDA antagonism is thought to interrupt central sensitization at the dorsal horn, so the change in signaling may outlast the drug’s presence in plasma. That is a plausible rationale for an intermittent protocol, and it is the one most of us rely on, but it has not been demonstrated as a duration of benefit in dogs. Describe it that way when a colleague or client asks why the injections are spaced the way they are.

Newer studies add information without settling the chronic-pain question

• A small randomized pilot study in 20 dogs undergoing TPLO found better perioperative analgesia when magnesium sulfate was combined with ketamine than with ketamine alone. An interesting adjunctive finding, not yet a practice standard.
• A 2024 pharmacokinetic study showed that an Omnipod system could deliver SQ ketamine to dogs and produce measurable plasma concentrations. It established delivery and exposure, not analgesic efficacy or a chronic outpatient protocol.
• In a retrospective study of 114 dogs and cats with cancer pain, outpatient IV ketamine-lidocaine infusions were well tolerated, and 76% of patients reported clinical improvement after the first infusion. Because the study spanned two species, lacked a control group, and combined ketamine with lidocaine, it cannot prove ketamine efficacy or support an SQ protocol. It does offer useful information about monitored infusion therapy for selected patients with refractory cancer pain.
• Other recent work has described short-lived behavioral effects after low-dose ketamine, including staring, head tremors, and disorientation in some dogs.

The bottom line: ketamine has not been critically studied for chronic pain in dogs, and no standard canine OA protocol exists. When we use it in a chronic case, the rationale comes from its mechanism, acute canine pain studies, human chronic-pain medicine, specialist experience, and the individual dog’s response.

That may be enough to support an informed trial in a carefully selected patient. It is not the same as controlled evidence of efficacy for canine OA.

Where SQ Ketamine May Fit in a Senior Pain Plan

A senior dog who is still struggling does not automatically need another medication. Before adding ketamine, go back through the pain plan and ask why it is not working.

Confirm that pain is the primary reason for the functional decline. Revisit the likely pain generator, adherence, administration, muscle loss, mobility, and the possibility that a new condition has appeared. A dog who suddenly struggles to rise may have progressive OA, but neurologic disease, generalized weakness, endocrine disease, hypotension, and deconditioning can all look the same at home.

SQ ketamine may be reasonable to consider when:

• pain remains functionally important despite a deliberate multimodal plan;
• central sensitization or a neuropathic component is suspected;
• better-supported options have been tried, are contraindicated, or are limited by the patient;
• current medications and comorbidities have been reviewed;
• the practice can observe the initial response and adverse effects; and
• the veterinarian and client have agreed on specific functional goals and a reassessment plan.

If the pain generator remains unclear, neurologic disease may be contributing, several centrally acting medications are already on board, or the patient’s comorbidities make the plan hard to predict, consultation may be more useful than adding ketamine empirically.

Document the 0.5 mg/kg SQ dose and the weekly-to-every-four-weeks interval as anecdotal and individualized. The record should include the functional outcome being monitored, the apparent duration of benefit, and the reason for repeating the treatment, changing the interval, or stopping.

Ketamine in Senior Dogs With Cardiac, Renal, or Hepatic Disease

The question is rarely “Can I use ketamine in a senior dog?” The useful questions are: What disease is present? How stable is it? Which route and dose am I considering? What else is the dog taking? What monitoring do I have?

Two practical points apply regardless of organ system. First, the SQ route depends on perfusion, so a hypotensive, dehydrated, or septic dog is unlikely to absorb the injection reliably and is not a candidate. Second, dose on lean body weight. Calculating on total body weight overshoots in an obese dog, and in giant breeds many clinicians scale the dose down rather than dosing linearly.

Cardiac disease

Ketamine can increase sympathetic tone, heart rate, blood pressure, cardiac output, and myocardial oxygen demand. Those effects may be tolerated in some anesthetic settings, but they deserve more attention in a dog with significant cardiac disease, tachyarrhythmia, systemic hypertension, or limited myocardial reserve.

A murmur alone does not answer the question. Consider the diagnosis and stage, current blood pressure and rhythm, cardiac medications, the proposed protocol, and available monitoring. No chronic SQ study has established a safety margin for dogs with cardiac disease. Significant or poorly characterized disease warrants individualized planning and, when appropriate, consultation with an anesthesiologist or cardiologist.

Renal disease

Ketamine undergoes hepatic biotransformation, including metabolism to norketamine, and its metabolites are eliminated in urine. Chronic kidney disease (CKD) is not an automatic contraindication, but repeated SQ ketamine has not been adequately studied in dogs with renal disease.

Consider hydration, perfusion, disease stability, blood pressure, concurrent medications, and the whole analgesic plan. No canine data tell us how a particular IRIS stage or creatinine value should change the SQ dose or interval.

Hepatic disease

Significant hepatic dysfunction may alter ketamine handling. Increased liver enzyme activity is not the same as impaired hepatic function, so look at the whole patient. Abnormal bilirubin, hypoalbuminemia, altered coagulation, or other evidence of reduced functional capacity should increase caution.

Age itself is not a reason to lower the dose or exclude ketamine. Frailty, body composition, organ function, cardiovascular reserve, concurrent disease, and the overall medication plan determine the risk.

Adverse Effects and Monitoring

Published chronic OA guidance describes sedation and agitation as uncommon adverse effects. Depending on dose, route, concurrent medications, and the patient, ketamine may also cause dysphoria, increased motor activity or muscle tone, salivation, nausea or vomiting, tachycardia, increased blood pressure, and altered recovery quality.

Monitoring should match the protocol. For an IV loading dose or CRI, monitor cardiovascular and respiratory variables, temperature, sedation or anesthetic depth as appropriate, pain, dysphoria, and concurrent drug effects.

For intermittent SQ use, give the first dose where the patient can be assessed for behavioral, cardiovascular, and neurologic effects. Send the caregiver home with clear instructions on what to watch for and when to call.

Ketamine is a DEA Schedule III controlled substance in the United States. Storage, access, documentation, inventory, and disposal must comply with federal and state requirements. It should not be administered epidurally or intrathecally; veterinary references warn of neurotoxicity by those routes.

How to Tell Whether Ketamine Helped

“The owner thought she might have had a better week” is not enough to justify ongoing treatment.

Before the first dose, choose two or three functional measures that matter to this dog:

• the time or effort required to rise;
• the ability to use a specific set of stairs;
• walk duration or willingness to walk;
• slipping or falling frequency;
• nighttime restlessness;
• the ability to posture for elimination; and
• participation in an activity pain had limited.

A repeated clinical metrology instrument such as the Canine Brief Pain Inventory, LOAD, or the Helsinki Chronic Pain Index adds structure. Video helps too. Ask the caregiver to record the same task on the same surface before treatment and at a defined time afterward.

Keep the rest of the plan as stable as the dog’s comfort allows if you want to know whether ketamine contributed. Document when improvement began, how long it lasted, and whether you met the predefined goals. If function does not improve or adverse effects outweigh the benefit, stop and reassess. A failed trial is still useful clinical information.

Ketamine vs. Amantadine for Chronic Pain in Dogs

Ketamine and amantadine are both NMDA receptor antagonists, but they are used differently and supported by different evidence.

Amantadine is given orally and has limited but direct canine OA evidence. In a randomized study of dogs with OA pain refractory to an NSAID, adding amantadine improved physical activity compared with placebo. Ketamine has stronger canine evidence for acute perioperative pain but has not been critically studied for chronic OA.

For a stable outpatient with chronic OA, amantadine may be easier to trial and reassess. For a hospitalized patient with severe acute pain or perioperative risk of central sensitization, ketamine may address a different need. The choice depends on the clinical problem, route, expected onset, monitoring, and patient tolerance.

In practice, clinicians often use the two together. Amantadine can take several weeks to show an effect, so some clinicians start it and use ketamine while they wait, then reassess both once amantadine has had a fair trial. That sequencing is clinical practice rather than a tested strategy.

How to Explain the Evidence to Clients

Clients may know ketamine as an anesthetic or recognize it from human medicine. A clear explanation might sound like this:

Ketamine affects a pain pathway that gets involved when the nervous system becomes more sensitive to ongoing pain. We have good veterinary evidence for using low doses around surgery. Some veterinarians also use it for chronic pain, but that use has not been studied as well in dogs. If we try it, we will watch for specific changes in function and stop if it does not provide a meaningful benefit.

That gives the client enough to consent to an off-label, evidence-limited trial and helps them participate in judging the response. The goal is to find out whether this dog is more comfortable and able to do more of what matters at home.

Conclusion

Ketamine has an established role in veterinary anesthesia and acute pain management. In dogs, the strongest evidence supports low-dose perioperative CRIs as part of a multimodal protocol.

Its role in chronic OA is less certain. Intermittent SQ ketamine is being used in practice, including 0.5 mg/kg SQ at intervals from weekly to every four weeks, but the dose and interval remain anecdotal. Controlled canine chronic-pain studies are still lacking.

For the right patient, ketamine may be a reasonable adjunct. The decision should start with four questions: Which ketamine protocol am I considering? What problem am I trying to solve? What risks does this patient carry? How will I know whether it helped?

For veterinarians who want to go deeper, Dr. Katie Bennett, DVM, DACVAA, teaches full lectures on the practical use of ketamine in general practice within the Senior Dog Veterinary Society curriculum. She covers how clinicians are currently using 0.5 mg/kg SQ at varying intervals, how to assess and adjust the interval for an individual patient, perioperative protocols, monitored infusions, patient selection, adverse effects, multimodal pain plans, and real clinical cases. SDVS members can also access case-based Rounds where specialists work through the questions that come up when these protocols meet senior patients with comorbidities.

Frequently Asked Questions